ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
25 announcements with these filters
Sun Pharma Advanced Research filed its monitoring agency report on warrant issue proceeds for the quarter ended September 30, 2026. The agency found no deviation from objects.
Sun Pharma Advanced Research Company Ltd reported revenue from operations of ₹30 Cr (+279.7% YoY) and a net loss of ₹24.4 Cr for Q2 FY27.
SPARC intimated its Board will meet November 2, 2026 to consider Q1 and H1 FY27 unaudited results. Insider trading window stays closed until 48 hours post-declaration.
Sun Pharma Advanced Research Company Ltd has filed its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
The company secured a favorable CESTAT order confirming its entitlement to a Rs. 27.51 Crore CENVAT credit refund. This concludes the litigation in the company's favor.
Sun Pharma Advanced Research Company Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026.
Sun Pharma Advanced Research Company has submitted an application to stock exchanges to reclassify certain members from 'Promoter Group' to 'Public' category.
SPARC held its 21st Annual General Meeting on August 10, 2026, via video conferencing. The meeting covered routine business, including adoption of financial statements.
Sun Pharma Advanced Research Company Limited submitted the Monitoring Agency Report for the quarter ended June 30, 2026. The report confirms zero deviation in utilizing proceeds from its Rs. 599.98 Crore warrant issue.
Sun Pharma Advanced Research Company Ltd reported revenue from operations of ₹39.9 Cr (+315.6% YoY) and a net loss of ₹20.8 Cr for Q1 FY27.
Sun Pharma Advanced Research Company Limited scheduled a Board Meeting for August 10, 2026. The meeting will consider unaudited financial results for the period ended June 2026.
Sun Pharma Advanced Research Company has received requests from certain Promoter Group members to reclassify their status to the 'Public' category.
Sun Pharma Advanced Research Company Ltd filed its quarterly shareholding pattern for the period ending June 30, 2026. The filing details equity holdings across promoter and public categories.
Sun Pharma Advanced Research Company submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report detailing ESG initiatives forms part of the Annual Report.
SPARC scheduled its 21st AGM for August 10, 2026, via video conference. Agenda includes adopting FY26 financials and appointing Anil Kumar Raghavan as MD and CEO.
Sun Pharma Advanced Research Company submitted its FY 2025-26 Annual Report. The 21st AGM is scheduled for August 10, 2026, via video conferencing.
SPARC appointed Anil Raghavan as Managing Director and CEO effective August 11, 2026. Dr. Rajamannar Thennati will retire from the Board on August 10, 2026.
The 21st AGM of Sun Pharma Advanced Research Company will be held on 10 Aug 2026 via video conference. Electronic voting is open until 3 Aug 2026.
Sun Pharma Advanced Research Company announced senior management changes. Mr. Prasanna Deshmukh is appointed as Functional Head of HR & Administration.
Sun Pharma Advanced Research Company terminated its license agreement with CMS Bridging DMCC. The company reports no material impact on its financial position or operations.
SPARC received ₹149.99 Crore from Shanghvi Finance via a preferential allotment of 3,85,10,000 warrants. The capital infusion strengthens the company's financial position for future growth.
SPARC's partner Ocuvex received a US FDA Complete Response Letter for the PDP-716 drug application. The FDA cited manufacturing inspection findings but raised no other issues.
SPARC allotted 3.85 crore convertible warrants at ₹155.80 each to Shanghvi Finance on a preferential basis. The ₹599.99 Crore raise strengthens capital for future growth.
Sun Pharma Advanced Research Company Ltd reported revenue from operations of ₹1,853 Cr (+6713.2% YoY) and net profit of ₹1,761 Cr for Q4 FY26.
SPARC reported audited FY26 results, highlighted by a ₹1,840.02 Crore income from a voucher sale. The company remains focused on pharmaceutical research and development.